Exclusive

Publication

Byline

ममता बनर्जी बोलीं कि वोट डालने से रोकने वाले को झाड़ू दिखाएं, जनता उन्हें ही दिखा रहीः अमित मालवीय

नई दिल्ली, अप्रैल 11 -- पश्चिम बंगाल विधानसभा चुनाव के बीच बीजेपी नेता अमित मालवीय ने मुख्यमंत्री ममता बनर्जी पर निशाना साधा है। उन्होंने कहा कि ममता ने पहले लोगों से अपील की थी कि जो लोग उन्हें वोट ड... Read More


लकड़ी काटने वाली मशीन से युवक घायल

हमीरपुर, अप्रैल 11 -- भरुआ सुमेरपुर। क्षेत्र के ग्राम चंद्रपुरवा बुजुर्ग में सुबह घर के अंदर लकड़ी काटते समय मशीन की आरी युवक के गाल में लग गई। इससे युवक गंभीर रूप से घायल हो गया। हालत गंभीर होने पर यु... Read More


Telangana: ATM machine stolen near police station in Rajanna Sircilla

Hyderabad, April 11 -- Unidentified persons stole a State Bank of India (SBI) ATM machine from Ellareddypet Mandal headquarters in Rajanna Sircilla district, Telangana during the early hours of Saturd... Read More


Spring memories of wartime resilience at Ky Anh Tunnels

Da Nang, April 11 -- Constructed deep inside enemy-held territory, the Ky Anh Tunnels remain a striking testament to the resilience and determination of revolutionary soldiers and residents of the for... Read More


Singapore Clinical Trial: 'Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the post-operative survival of glaucoma drainage devices'

Singapore, April 11 -- The Health Sciences Authority received information related to the study titled ''Establishing the role of mitomycin C and systemic non-steroidal anti-inflammatory drugs in the p... Read More


Singapore Clinical Trial: IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-986507) versus Platinum-based Chemotherapy in Patients with EGFR-mutated Non-small Cell Lung Cancer and Disease Progression on EGFR Tyrosine Kinase Inhibitor Therapy.

Singapore, April 11 -- The Health Sciences Authority received information related to the study titled 'IZABRIGHT-Lung01: A Randomized, Open-label, Phase 2/3 Study of Izalontamab Brengitecan (BMS-98650... Read More


Singapore Clinical Trial: ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemotherapy Versus Bevacizumab in Combination with Chemotherapy in Participants with Previously Untreated, Unresectable, or Metastatic Colorectal Cancer

Singapore, April 11 -- The Health Sciences Authority received information related to the study titled 'ROSETTA CRC-203: A Blinded, Randomized Phase 2/3 Study of Pumitamig in Combination with Chemother... Read More


Singapore Clinical Trial: A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety and Efficacy of L606 (Treprostinil Liposome Inhalation Suspension) in Participants with Pulmonary Hypertension Associated with Interstitial Lung Disease (WHO Group 3)

Singapore, April 11 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Multicenter, Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safe... Read More


Singapore Clinical Trial: A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) Monotherapy versus Physician’s Choice of Chemotherapy in Participants with B7-H4-Selected Advanced/Metastatic Endometrial Cancer Who Progressed On or After Platinum-Based Chemotherapy and Anti-PD-1/Anti-PD-L1 Therapy (BLUESTAR-Endometrial01)

Singapore, April 11 -- The Health Sciences Authority received information related to the study titled 'A Phase III, Randomized, Open-Label, Multicenter, Global Study of Puxitatug Samrotecan (AZD8205) ... Read More


Singapore Clinical Trial: DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig in combination with atezolizumab, carboplatin, and etoposide vs. atezolizumab, carboplatin, and etoposide as first-line treatment in patients with extensive-stage small cell lung cancer

Singapore, April 11 -- The Health Sciences Authority received information related to the study titled 'DAREON®-Lung 1: A Phase III multi-center, open-label, randomised trial of intravenous obrixtamig ... Read More